Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS

Accessed on 5 May 2014 from http://www.syntheticbiologics.com/2014-04-29-Synthetic-Biologics-Reports-UCLA-Announcement-of-Preliminary-Positive-Topline-Efficacy-and-Safety-Results-from-Investigator-Led-Phase-II-Study-of-Trimesta-for-Relapsing-Remitting-Multiple-Sclerosis.